Logo image of APTO

APTOSE BIOSCIENCES INC (APTO) Stock Fundamental Analysis

NASDAQ:APTO - Nasdaq - CA03835T3091 - Common Stock - Currency: USD

0.1801  +0 (+2.21%)

Premarket: 0.188 +0.01 (+4.39%)

Fundamental Rating

1

APTO gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 572 industry peers in the Biotechnology industry. APTO may be in some trouble as it scores bad on both profitability and health. APTO is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

APTO had negative earnings in the past year.
APTO had a negative operating cash flow in the past year.
In the past 5 years APTO always reported negative net income.
APTO had a negative operating cash flow in each of the past 5 years.
APTO Yearly Net Income VS EBIT VS OCF VS FCFAPTO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -20M -40M -60M

1.2 Ratios

Looking at the Return On Assets, with a value of -327.57%, APTO is doing worse than 95.58% of the companies in the same industry.
Industry RankSector Rank
ROA -327.57%
ROE N/A
ROIC N/A
ROA(3y)-185.13%
ROA(5y)-125.06%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
APTO Yearly ROA, ROE, ROICAPTO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 500 1K 1.5K

1.3 Margins

APTO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
APTO Yearly Profit, Operating, Gross MarginsAPTO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023

More info and screens

1

2. Health

2.1 Basic Checks

Compared to 1 year ago, APTO has more shares outstanding
APTO has more shares outstanding than it did 5 years ago.
APTO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
APTO Yearly Shares OutstandingAPTO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M
APTO Yearly Total Debt VS Total AssetsAPTO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

2.2 Solvency

APTO has an Altman-Z score of -79.87. This is a bad value and indicates that APTO is not financially healthy and even has some risk of bankruptcy.
APTO's Altman-Z score of -79.87 is on the low side compared to the rest of the industry. APTO is outperformed by 96.64% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -79.87
ROIC/WACCN/A
WACCN/A
APTO Yearly LT Debt VS Equity VS FCFAPTO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M 100M

2.3 Liquidity

A Current Ratio of 1.05 indicates that APTO should not have too much problems paying its short term obligations.
The Current ratio of APTO (1.05) is worse than 87.79% of its industry peers.
APTO has a Quick Ratio of 1.05. This is a normal value and indicates that APTO is financially healthy and should not expect problems in meeting its short term obligations.
APTO has a Quick ratio of 1.05. This is amonst the worse of the industry: APTO underperforms 86.02% of its industry peers.
Industry RankSector Rank
Current Ratio 1.05
Quick Ratio 1.05
APTO Yearly Current Assets VS Current LiabilitesAPTO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 62.55% over the past year.
EPS 1Y (TTM)62.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%78.98%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, APTO will show a quite strong growth in Earnings Per Share. The EPS will grow by 18.54% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y76.35%
EPS Next 2Y30.79%
EPS Next 3Y20.94%
EPS Next 5Y18.54%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
APTO Yearly Revenue VS EstimatesAPTO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 100M 200M 300M 400M 500M
APTO Yearly EPS VS EstimatesAPTO Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 5 -5 -10 -15

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for APTO. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for APTO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
APTO Price Earnings VS Forward Price EarningsAPTO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
APTO Per share dataAPTO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.5 -1 -1.5 -2 -2.5

4.3 Compensation for Growth

A more expensive valuation may be justified as APTO's earnings are expected to grow with 20.94% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y30.79%
EPS Next 3Y20.94%

More info and screens

0

5. Dividend

5.1 Amount

APTO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

APTOSE BIOSCIENCES INC

NASDAQ:APTO (2/4/2025, 8:26:59 PM)

Premarket: 0.188 +0.01 (+4.39%)

0.1801

+0 (+2.21%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-08 2024-11-08/amc
Earnings (Next)N/A N/A
Inst Owners15.08%
Inst Owner Change0.6%
Ins Owners0.57%
Ins Owner Change5.41%
Market Cap3.52M
Analysts82.5
Price Target4.08 (2165.41%)
Short Float %8.03%
Short Ratio0.16
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)66.9%
Min EPS beat(2)64.27%
Max EPS beat(2)69.52%
EPS beat(4)4
Avg EPS beat(4)37.14%
Min EPS beat(4)3.29%
Max EPS beat(4)69.52%
EPS beat(8)6
Avg EPS beat(8)16.25%
EPS beat(12)9
Avg EPS beat(12)9.71%
EPS beat(16)12
Avg EPS beat(16)10.05%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-72.41%
EPS NQ rev (1m)71.07%
EPS NQ rev (3m)55.97%
EPS NY rev (1m)41.41%
EPS NY rev (3m)58.56%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.97
EYN/A
EPS(NY)-2.23
Fwd EYN/A
FCF(TTM)-1.9
FCFYN/A
OCF(TTM)-1.9
OCFYN/A
SpS0
BVpS-0.47
TBVpS-0.47
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -327.57%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-185.13%
ROA(5y)-125.06%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.05
Quick Ratio 1.05
Altman-Z -79.87
F-Score2
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)64.76%
Cap/Depr(5y)62.67%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)62.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%78.98%
EPS Next Y76.35%
EPS Next 2Y30.79%
EPS Next 3Y20.94%
EPS Next 5Y18.54%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y28.51%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year41.1%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y6.48%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y6.39%
OCF growth 3YN/A
OCF growth 5YN/A